Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma.

Rose Prince

2018-11-23 09:39:00 Fri ET

Former White House chief economic advisor Gary Cohn points out that there is no instant cure for the Sino-U.S. trade dilemma. After the U.S. midterm elections, the major trade issues remain on the radar (as Republicans secure a stronger majority in Senate and Democrats flip the House of Representatives).

First, the U.S. bilateral trade deficit with China is about $300 billion, and President Trump seems to be uncomfortable with the key fact that this trade deficit is so large. Cohn disagrees with the presidential view because he alternatively views this trade deficit as $300 billion worth of goods that America can purchase from China in a cost-effective way. However, Cohn suggests that the Chinese administration can readily resolve this issue by buying more American goods to better balance Sino-U.S. trade.

Second, the more pertinent issue is the historically unfair situation that China often forces technology transfer when U.S. tech corporations enter the mainland market. Chinese regulations require foreign tech companies to build onshore data centers and IT research labs so that Sino-American technology transfer takes place. China thus fails to pay for foreign intellectual properties such as patents, trademarks, and copyrights etc. This core issue persists at the heart of the current Sino-U.S. trade impasse.

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

President Trump ramps up 25% tariffs on $200 billion Chinese imports soon after China backtracks on the Sino-U.S. trade agreement.

Rose Prince

2019-05-09 10:28:00 Thursday ET

President Trump ramps up 25% tariffs on $200 billion Chinese imports soon after China backtracks on the Sino-U.S. trade agreement.

President Trump ramps up 25% tariffs on $200 billion Chinese imports soon after China backtracks on the Sino-American trade agreement. U.S. trade envoy Robe

+See More

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups.

Becky Berkman

2019-08-09 18:35:00 Friday ET

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups.

Nobel Laureate Joseph Stiglitz maintains that globalization only works for a few elite groups; whereas, the government should now reassert itself in terms o

+See More

Admitting China to the WTO seems ineffective in imparting economic freedom and democracy to the communist regime.

Dan Rochefort

2018-07-27 10:35:00 Friday ET

Admitting China to the WTO seems ineffective in imparting economic freedom and democracy to the communist regime.

Admitting China to the World Trade Organization (WTO) and other international activities seems ineffective in imparting economic freedom and democracy to th

+See More

President Trump criticizes his new Fed Chair Jerome Powell for accelerating the current interest rate hike.

Joseph Corr

2018-08-21 11:40:00 Tuesday ET

President Trump criticizes his new Fed Chair Jerome Powell for accelerating the current interest rate hike.

President Trump criticizes his new Fed Chair Jerome Powell for accelerating the current interest rate hike with greenback strength. This criticism overshado

+See More

Fundamental value investors find it more difficult to ferret out individual stocks.

James Campbell

2017-06-03 05:35:00 Saturday ET

Fundamental value investors find it more difficult to ferret out individual stocks.

Fundamental value investors, who intend to manage their stock portfolios like Warren Buffett and Peter Lynch, now find it more difficult to ferret out indiv

+See More

The global market for GLP-1 weight-loss medications can grow substantially to benefit more than 1 billion people worldwide by 2030.

Monica McNeil

2025-10-31 12:26:00 Friday ET

The global market for GLP-1 weight-loss medications can grow substantially to benefit more than 1 billion people worldwide by 2030.

With respect to wider weight loss treatment and obesity treatment, the global market for GLP-1 medications now grows substantially to benefit more than 1 bi

+See More